{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:36:19Z","timestamp":1773272179282,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL107151"],"award-info":[{"award-number":["HL107151"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI072265"],"award-info":[{"award-number":["AI072265"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI36443"],"award-info":[{"award-number":["AI36443"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jaip.2018.04.030","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T04:24:17Z","timestamp":1536207857000},"page":"1446-1453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options"],"prefix":"10.1016","volume":"6","author":[{"given":"Paneez","family":"Khoury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce S.","family":"Bochner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.04.030_bib1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.04.030_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.iac.2015.05.003","article-title":"Eosinophilia in infectious diseases","volume":"35","author":"O'Connell","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2018.04.030_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.iac.2015.05.004","article-title":"Eosinophilia associated with disorders of immune deficiency or immune dysregulation","volume":"35","author":"Williams","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2018.04.030_bib4","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jaci.2015.04.005","article-title":"Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics","volume":"136","author":"Blumenthal","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.030_bib5","doi-asserted-by":"crossref","first-page":"e9688","DOI":"10.1097\/MD.0000000000009688","article-title":"Drug-induced eosinophilic pneumonia: a review of 196 case reports","volume":"97","author":"Bartal","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2018.04.030_bib6","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2018.04.030_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.iac.2015.05.001","article-title":"Eosinophilia in rheumatologic\/vascular disorders","volume":"35","author":"Tamaki","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2018.04.030_bib8","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3389\/fimmu.2017.00484","article-title":"Eosinophils in autoimmune diseases","volume":"8","author":"Diny","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2018.04.030_bib9","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.04.030_bib10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12032-013-0815-1","article-title":"Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance","volume":"31","author":"Helbig","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.jaip.2018.04.030_bib11","doi-asserted-by":"crossref","first-page":"AB277","DOI":"10.1016\/j.jaci.2017.12.883","article-title":"Myeloproliferative hypereosinophilic syndrome: retrospective analysis of cytogenetic and molecular features [abstract]","volume":"141","author":"Pongdee","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.030_bib12","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jaip.2017.08.001","article-title":"Biologic agents for the treatment of hypereosinophilic syndromes","volume":"5","author":"Kuang","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.030_bib13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaip.2018.04.030_bib14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.030_bib15","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaip.2015.06.009","article-title":"Hematologic malignancies identified in patients with hypereosinophilia and hypereosinophilic syndromes","volume":"3","author":"Jin","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.030_bib16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/jcp.34.12.1343","article-title":"Tumour-associated eosinophilia: a review","volume":"34","author":"Lowe","year":"1981","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jaip.2018.04.030_bib17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajh.24880","article-title":"World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gotlib","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2018.04.030_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-4632.2004.01975.x","article-title":"Erythroderma\/exfoliative dermatitis: a synopsis","volume":"43","author":"Sehgal","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2018.04.030_bib19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","author":"Simon","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.04.030_bib20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2018.04.030_bib21","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaip.2017.07.008","article-title":"New and anticipated therapies for severe asthma","volume":"5","author":"Peters","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.030_bib22","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.04.030_bib23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.030_bib24","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-term clinical outcomes of high dose mepolizumab treatment for hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.030_bib25","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.030_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.04.030_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.04.030_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2018.04.030_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/asheducation-2015.1.92","article-title":"Eosinophilia: a pragmatic approach to diagnosis and treatment","volume":"2015","author":"Klion","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaip.2018.04.030_bib30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","article-title":"Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes","volume":"132","author":"Panch","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.04.030_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3988\/jcn.2017.13.1.77","article-title":"Clinical characteristics and treatment response of peripheral neuropathy in the presence of eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome): experience at a single tertiary center","volume":"13","author":"Cho","year":"2017","journal-title":"J\u00a0Clin Neurol"},{"key":"10.1016\/j.jaip.2018.04.030_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","article-title":"Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials","volume":"43","author":"Samson","year":"2013","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaip.2018.04.030_bib33","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2017.07.027","article-title":"Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis","volume":"5","author":"Thiel","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.04.030_bib34","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.04.030_bib35","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaip.2018.04.030_bib36","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","article-title":"The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management","volume":"103","author":"Gotlib","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.04.030_bib37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/all.12843","article-title":"Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome","volume":"71","author":"Khoury","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.04.030_bib38","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"118","author":"Walz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2018.04.030_bib39","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","article-title":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"59","author":"Strati","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaip.2018.04.030_bib40","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","article-title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene","volume":"94","author":"Rumi","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaip.2018.04.030_bib41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","article-title":"Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes","volume":"94","author":"Schwaab","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaip.2018.04.030_bib42","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1200\/JCO.2007.15.5770","article-title":"Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes","volume":"26","author":"Sekeres","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2018.04.030_bib43","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/archderm.141.12.1556","article-title":"Soak and smear: a standard technique revisited","volume":"141","author":"Gutman","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2018.04.030_bib44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MD.0000000000000088","article-title":"The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3\u2212CD4+ aberrant T-cell phenotype","volume":"93","author":"Lefevre","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2018.04.030_bib45","doi-asserted-by":"crossref","unstructured":"Hanbali A, Shaheen M, Alfraih F, Al-Otaibi W, El Fakih R, Owaidah T, et\u00a0al. A case of T-cell lymphoproliferative disorder associated with hypereosinophilia with excellent response to mycophenolate mofetil [published online ahead of print February 1, 2017]. Hematol Oncol Stem Cell Ther. https:\/\/doi.org\/10.1016\/j.hemonc.2016.11.001.","DOI":"10.1016\/j.hemonc.2016.11.001"},{"key":"10.1016\/j.jaip.2018.04.030_bib46","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.intimp.2013.04.033","article-title":"Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome","volume":"16","author":"Tabata","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaip.2018.04.030_bib47","first-page":"S52","article-title":"Churg Strauss syndrome\u2013successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment","volume":"22","author":"Metzler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaip.2018.04.030_bib48","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.04.030_bib49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fmed.2017.00240","article-title":"Clinical and biological markers in hypereosinophilic syndromes","volume":"4","author":"Khoury","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2018.04.030_bib50","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2018.04.030_bib51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000085560","article-title":"Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis","volume":"114","author":"Butterfield","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jaip.2018.04.030_bib52","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.leukres.2006.10.005","article-title":"\u2018Idiopathic\u2019 eosinophilia with an occult T-cell clone: prevalence and clinical course","volume":"31","author":"Vaklavas","year":"2007","journal-title":"Leuk Res"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818303076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818303076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:15:21Z","timestamp":1761974121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219818303076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S2213219818303076"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.04.030","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}